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Background
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent skin cancer, with an estimated 400,000 new cases reported yearly in the United States (1) . Although metastasis is relatively uncommon, prognosis in patients with lymph node positive cSCC is poor and 5-year survival rates are low (2) .
Furthermore, advanced and often inoperable, loco-regional disease is frequent with cSCC and such patients would benefit from effective, targeted chemotherapies. The hunt for genetic drivers and thus potential targets for cSCC therapy is hampered by a mutation burden greater than any other known cancer with metastatic potential (3) (4) (5) , only exceeded by basal cell carcinoma of the skin (S1). Deep sequencing of cSCC has identified key driver mutations in tumor suppressor genes (3) (4) (5) which are difficult to target therapeutically as it is easier to inhibit the action of a protein than it is to replace its function when missing. A pathway centric approach may be a more appropriate route for therapy development because somatic, cancer-promoting mutations may affect multiple nodes within the same pathway leading to downstream activation (6). We recently identified frequent CARD11 mutations in cSCC, which lead to aberrant NFkB signalling (7). Nuclear factor kappa-b (NFκB) signaling plays a crucial role regulating proliferation and differentiation in the epidermis and alterations can lead to skin pathologies with significant burden to human health such as psoriasis and cSCC. One gene reported as integral to a number of ubiquitous signaling pathways (including NFκB) is CREBBP which encodes the protein CBP, a transcriptional co-factor with lysine acetyltransferase activity and close homology to p300 (S2) . CREBBP loss of function (LOF) mutations are frequently identified in a range of different cancers such as lymphomas and carcinomas of the bladder and esophagus (S3-5) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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Questions Addressed
We previously identified CREBBP mutation in 35% of 20 cSCC using exome sequencing (4). Here we address whether CREBBP mutation is present in a larger cohort of cSCC samples (n=91).
Experimental Design
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Results
To define CREBBP mutation in a larger cohort of human cSCC we used targeted re-sequencing of 91 samples previously isolated and used to re-sequence potential driver genes such as NOTCH1, TP53 and CARD11, as described (4, 7) . CREBBP mutation frequency was high (33/91 cSCC tumors, 36%, compared with 7/20, 35%, in the original exome sequencing cohort). Thus, CREBBP is frequently mutated in human cSCC (mutations listed in Supporting Table S1 ). We next compared the spectrum of CREBBP mutation in cSCC with those reported for other tumors in the catalogue of somatic mutations in cancer (COSMIC) (S6) and identified that 50/51 cSCC mutations were missense, in contrast to those reported in COSMIC (n=758) where >25% of mutations were either non-sense or insertion/ deletion mutations leading to frame-shift and a premature termination codon (PTC) ( Figure 1A ). The majority of such mutations are predicted to result in expression of a truncated protein that is either greatly reduced or absent as a result of non-sense mediated decay (NMD). Analyzing mutation spectrum by tissue type in COSMIC identified certain tumor groups with greater than 33% mutations leading to PTC such as the hematopoetic and lymphatic system as well as esophagus. Bladder harboured 75% non-sense or insertion/ deletion mutations ( Figure 1B) .
Two previous studies support our observations that loss of function mutation in CREBBP is not prevalent in primary cSCC; Durinck and colleagues identified 1 missense mutation from 8 cSCC (3), while Pickering and colleagues identified 24 mutations in a cohort of 39 aggressive, primary cSCC, 21 of which were missense or silent (5) .
Given the spectrum of mutation in cSCC we speculated whether cSCC CREBBP mutation, unlike other tumors with a high CREBBP mutation frequency, does not result in CBP loss of function. To address this immuno-histochemistry (IH) was used to interrogate the expression level and distribution of CREBBP in 
Conclusion
CREBBP is regularly found to be inactivated through loss of function mutations in a range of malignancies (S3-5) . In contrast we find cSCC harbor missense mutation, and very few mutations that predict loss of function. Furthermore, we identify CBP in all 21 cSCC examined, indicating that protein is expressed and localizes to the correct compartment. It is unclear at this time, however, what role CBP may have in cSCC, but it is interesting to note that CBP/p300 is critical for efficient removal of UVinduced pyrimidine dimers (S7) . Furthermore, recent genomic analysis of 29 lymph node metastases from primary cSCC showed frequent (28%) CREBBP mutation (9) but here the majority of alterations (6/8) were truncating or insertion/ deletion mutations predicted to lead to LOF. This result may indicate that CBP inactivation is associated with tumor progression in cSCC and agrees with our IH observation, also in a limited number of samples, that a degree of CBP loss is observed in high grade tumors ( Figure   2C ). However, these observations will need to be confirmed, and the data presented here together with the recent finding that, unlike NOTCH1, CREBBP mutation is not frequent or positively selected for in normal, sun-exposed skin (10), suggests that CREBBP mutation is unlikely to be an early event in squamous cell carcinogenesis. wrote the paper.
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Sequencing
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Immunohistochemistry (IH)
Immunohistochemical staining was performed on formalin-fixed paraffin-embedded cSCC tissue specimens and normal skin specimens. Tissue sections were cut at a thickness of 3 µm onto 3-aminopropyltrioxysilane-coated slides and dried overnight in a 45 o C oven followed by de-waxing and dehydration in xylene and industrial methylated spirits. Antigen retrieval was performed by incubating sections in TRIS-EDTA-citrate antigen unmasking solution (5g EDTA, 2.5g TRIS base and 3.2g sodium citrate in 1 litre of distilled water, pH adjusted to 8.1 with sodium hydroxide) for 35 minutes in a microwave set to full power. Endogenous peroxidase activity was blocked at ambient temperature in 3%
hydrogen peroxide in distilled water for 15 minutes (cSCC) or 45 minutes (normal skin). A monoclonal antibody against the C-terminus of human CREBBP (CBP (C-1): sc-7300; Santa Cruz Biotechnology Inc, Santa Cruz, CA) was applied as primary antibody for 40 minutes at ambient temperature at a dilution of 1:10. Incubation with secondary biotinylated antibody followed by streptavidin-biotin-peroxidase complex was performed using the Vector Elite ABC kit (Vector Laboratories, CA, USA) according to the manufacturer's instructions with diaminobenzidine as the chromogen and haematoxylin as counterstain.
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